Clinical Trial Update: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating tiragolumab in combination with atezolizumab for recurrent glioblastoma (IDH-wildtype) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Tecentriq (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Glioblastoma, IDH-Wildtype | Phase 2 | Status: WITHDRAWN